Enorama Pharma AB (publ) Overview
Get informed when a big investor buys or sells
+ Follow118.31%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Enorama Pharma AB (publ)'s return on equity stands at 118.31%. That is above the sector sector average of 11.85%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Enorama Pharma AB (publ) sits higher the its sector benchmark (11.85%) with a ROE of 118.31%. That is roughly 898.2% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
A ROE of 118.31% for Enorama Pharma AB (publ) means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.
The history chart shows how Enorama Pharma AB (publ)'s ROE evolved across reporting periods, while the comparison chart places ERMA.ST next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
